An Integrated Reverse Engineering Approach Toward Rapid drug Re positioning for Alzheimer's Disease
Description: Alzheimer’s disease (AD) is a chronic and progressive neurodegenerative disorder that causes enormous personal and societal burdens. Currently there exist no cures for AD. In this project titled “An integrated reverse engineering approach toward rapid drug repositioning for Alzheimer’s disease,” we propose to develop an innovative integrated drug repositioning strategy that combines novel computational drug prediction, novel computational brain-blood-barrier (BBB) permeability prediction, retrospective large-scale clinical corroboration, and prospective experimental testing to rapidly identify repositioned anti-AD drug candidates. The output of our project will be a list of ranked repositioned drug candidates with interpretable mechanisms of action, high BBB permeability in humans, supporting clinical efficacy evidence gathered from ‘real-world’ AD patients, and demonstrated efficacy in mouse models of AD. We anticipate that these findings can be expeditiously translated into clinical trials and benefit AD patients. Our study will generate a large amount of data/knowledge/hypotheses that could serve as a starting point for others to conduct hypothesis- driven biomedical and clinical drug repositioning studies in different animal models of AD and in patients.
Funder: National Institute on Aging
Funding type: research
Funder scheme: R01
Start date: 2017-09-15
End date: 2024-05-31
Investigator: RONG XU
Institution: CASE WESTERN RESERVE UNIVERSITY
Funded outputs count: 104
Funder award ID: R01AG057557
OpenAlex ID: G7260393372